<DOC>
	<DOCNO>NCT02146456</DOCNO>
	<brief_summary>Colloid solution generally use maintain intravascular volume . It report impair blood coagulation vivo vitro crystalloid prolong coagulation time decrease clot strength . The formed fibrin clot vulnerable fibrinolysis case use colloid . Dilution plasmin vitro colloid enhances fibrinolysis primarily diminish Î±2-antiplasmin-plasmin interaction . Tranexamic acid antifibrinolytics competitively inhibit activation plasminogen , bind specific site plasminogen plasmin , molecule responsible degradation fibrin , protein form framework blood clot . It use treat prevent excessive blood loss surgery medical condition . Gastrointestinal effect , dizziness , fatigue , headache , hypersensitivity reaction , potential risk thrombosis report adverse effect tranexamic acid . We hypothesize inhibition plasmin tranexamic acid colloid administration improve colloid-induced clot strength impairment .</brief_summary>
	<brief_title>Rotational Thromboelastography Study Tranexamic Acid Colloid Infusion</brief_title>
	<detailed_description />
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Femur Head Necrosis</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients undergoing total hip replacement arthroplasty , diagnose avascular necrosis femoral head degenerative arthritis hip American Society Anesthesiologist I II Patients receive intraoperative transfusion Patients receive thrombin Patients venous thromboembolism Patients renal hepatic disease Patients coagulopathy Patient heart failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>